Disease Progression and Treatment Responses in a Prospective DMARD-naive Seropositive Early Rheumatoid Arthritis Cohort: Does Gender Matter?

Journal of Rheumatology - Tập 37 Số 12 - Trang 2475-2485 - 2010
Damini Jawaheer1, Paul Maranian2,3,4,5,6,7,8,9,10,11, Grace Park2,3,4,5,6,7,8,9,10,11, Maureen Lahiff2,3,4,5,6,7,8,9,10,11, Sogol Amjadi2,3,4,5,6,7,8,9,10,11, Harold E. Paulus2,3,4,5,6,7,8,9,10,11
1Center for Neurobehavioral Genetics, and Division of Rheumatology, University of California at Los Angeles, USA.
2Amgen, Inc., Thousand Oaks
3CA, USA
4Center for Genetics, Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, CA 94609-1609, USA.
5Center for Neurobehavioral Genetics, University of California at Los Angeles, currently Center for Genetics, Children's Hospital Oakland Research Institute; P. Maranian, MS;
6Center for Neurobehavioral Genetics, and the Division of Rheumatology, University of California at Los Angeles; the Center for Genetics, Children's Hospital Oakland Research Institute, Oakland;
7Division of Rheumatology, University of California at Los Angeles; G. Park, PhD, Division of Rheumatology,
8NIH Multipurpose Arthritis and Musculoskeletal Disease
9School of Public Health, University of California at Berkeley, California, USA
10School of Public Health, University of California at Berkeley
11University of California at Los Angeles, currently Amgen Inc.;

Tóm tắt

Objective.

To assess gender differences in disease characteristics and treatment responses over time in a disease-modifying antirheumatic drug (DMARD)-naive seropositive early rheumatoid arthritis (RA) cohort.

Methods.

Patients with polyarticular disease who were DMARD-naive and had seropositive early RA (< 14 months) were recruited by the Western Consortium of Practicing Rheumatologists. Each patient was examined at study entry, after 6 and 12 months, and yearly thereafter. Clinical and demographic data were collected. We investigated gender differences in baseline disease characteristics and treatment using chi-squared, Mann-Whitney U, and t tests. We used generalized estimating equations (GEE) models for repeated measures to examine whether the rate of change of specific disease outcomes during the first 2 years after DMARD initiation was significantly influenced by gender.

Results.

At baseline, men (n = 67) and women (n = 225) had similar disease activity and radiographic damage; men, however, had significantly worse erosion, while women had worse joint space narrowing. Despite similar treatment, women had worse disease progression over the 2-year followup, as assessed by trends in Disease Activity Score 28/erythrocyte sedimentation rate (DAS28-ESR4), physician global scores, and tender joint counts. In the GEE model, gender was significantly associated with the rate of change of DAS28-ESR4 scores (p = 0.009), although not independently associated with disease activity. Self-reported measures (Health Assessment Questionnaire-Disability Index, patient global scores, fatigue, pain) were worse among women at baseline and throughout the study period. Men were more likely to achieve remission.

Conclusion.

At baseline, men and women had similar disease activity and joint damage. Responses to treatment over time were better among men in this prebiologic era; women had worse progression despite similar treatment.

Từ khóa


Tài liệu tham khảo

Silman AJ Hochberg MC . Rheumatoid arthritis. Epidemiology of the rheumatic diseases. 2nd ed. New York: Oxford University Press; 2001:31–70.

10.1136/ard.2008.102244

Leeb, 2007, Disease activity score-28 values differ considerably depending on patient’s pain perception and sex, J Rheumatol, 34, 2382

MacGregor, 1995, HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity, J Rheumatol, 22, 1032

10.1002/art.22120

10.1002/art.1780370408

Da Silva, 1992, The effects of gender and sex hormones on outcome in rheumatoid arthritis, Baillieres Clin Rheumatol, 6, 196, 10.1016/S0950-3579(05)80344-9

Wilder, 1996, Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis, J Rheumatol, 23, 10

Kuiper, 2001, Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis, J Rheumatol, 28, 1809

Tengstrand, 2004, The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years, J Rheumatol, 31, 214

10.1196/annals.1351.019

Sokka, 2009, Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study, Arthritis Res Ther, 11, R7

10.1002/1529-0131(199805)41:5<817::AID-ART7>3.0.CO;2-S

10.1136/ard.2006.056937

10.1136/ard.2008.102244

10.3899/jrheum.080724

Mancarella, 2007, Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study, J Rheumatol, 34, 1670

10.1002/art.23794

10.1136/ard.2007.084897

Gossec, 2005, Influence of sex on disease severity in patients with rheumatoid arthritis, J Rheumatol, 32, 1448

10.1002/1529-0131(200012)43:12<2743::AID-ANR14>3.0.CO;2-A

10.1002/art.1780310302

van Gestel, 1999, ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology, J Rheumatol, 26, 705

10.1002/art.1780140605

10.1002/art.1780281203

10.1002/art.1780330403

10.1002/art.1780360601

10.1002/art.1780380107

10.1136/bmj.286.6361.266

Wener, 2000, The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration, J Rheumatol, 27, 2351

10.1146/annurev.pu.14.050193.000355

Voulgari, 2004, Early rheumatoid arthritis: does gender influence disease expression?, Clin Exp Rheumatol, 22, 165

10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9

10.1002/1529-0131(199904)42:3<588::AID-ANR33>3.0.CO;2-G

Jonsson, 1998, Does smoking stimulate rheumatoid factor production in non-rheumatic individuals?, Apmis, 106, 970, 10.1111/j.1699-0463.1998.tb00247.x